- In January 2025, Pfizer Inc., a global leader in pediatric healthcare, announced the launch of its Breztri Aerosphere for the management of pediatric asthma in the European Union, following approval from the European Medicines Agency (EMA). The Breztri Aerosphere inhaler is designed to provide effective control of asthma symptoms with a combination of two powerful corticosteroid and long-acting beta-agonist drugs. The launch aims to help improve asthma management in children with moderate to severe persistent asthma by offering a convenient, once-daily inhalation therapy
- In October 2024, Sanofi introduced its new Dupixent injection for the treatment of pediatric atopic dermatitis in children aged six years and older. This medication is designed to help manage severe eczema in pediatric patients, offering a biologic solution for reducing inflammation and preventing flare-ups. The launch of Dupixent aims to improve the quality of life for children with this chronic skin condition and further expand the treatment options available to pediatric dermatology specialists
- In September 2024, Novartis announced the successful completion of Phase 3 trials for its Kymriah pediatric cancer treatment. The treatment, based on CAR T-cell therapy, is now approved for pediatric patients with acute lymphoblastic leukemia (ALL). This breakthrough therapy is expected to provide a life-saving option for children who have failed other treatment modalities and presents a new frontier in pediatric oncology
- In December 2024, Johnson & Johnson introduced its innovative pediatric vaccination solution, Janssen's RSV vaccine for infants, at a global health conference. The vaccine is expected to reduce the incidence of respiratory syncytial virus (RSV) infections, a common cause of severe respiratory illness in children. The vaccine has shown promising results in early clinical trials and is anticipated to be widely available in the upcoming years, significantly contributing to the prevention of respiratory diseases in children
